Alpha Cognition Inc., a biopharmaceutical company developing treatments for neurodegenerative disorders, reported strong commercial progress for its FDA-approved Alzheimer’s drug ZUNVEYL in the first quarter of 2026. The company generated approximately $3.5 million in net ZUNVEYL product revenue, representing 40% sequential growth over Q4 2025 net product revenues of $2.5 million. Cumulative net product revenue totaled $10.3 million through the first four full quarters since ZUNVEYL’s launch. March was the strongest demand month since launch, with approximately 75% of active prescribers generating repeat prescriptions.
ZUNVEYL is the first new oral Alzheimer’s treatment approved in more than 15 years. The company dispensed 6,054 bottles in Q1, representing 23% quarter-over-quarter growth with demand increasing meaningfully throughout the quarter. March demand increased approximately 29% over February. The company’s healthcare provider writer base grew 23% quarter-over-quarter to 1,060, and the number of prescribers called on expanded 93% quarter-over-quarter to approximately 3,762, reflecting the impact of a fully staffed 60-person customer-facing field team. The company reached 2,502 unique nursing homes in Q1, 26% more than Q4, and called on approximately 7,900 total healthcare providers.
Medicare Part D contracts with two major pharmacy benefit managers cover approximately 45 million lives with no prior authorization requirements for ZUNVEYL. Current implementation across downstream plans represents approximately 16% of total contracted business, with expansion expected through mid-2026. Clinical studies are advancing, with BEACON enrollment substantially complete and topline data anticipated in early Q3 2026, ahead of the original Q4 target. CONVERGE, a 400-patient retrospective chart review, initiated in April 2026 with topline data expected in Q3.
The company reported a net loss of $6.5 million for Q1 2026, compared to $1.7 million in Q1 2025. Total operating expenses were approximately $11.6 million. The company’s cash position stood at $54.2 million as of March 31, 2026, compared to $66.0 million as of December 31, 2025. Management reiterates full-year 2026 operating expense guidance of approximately $54-$58 million and remains on track to achieve profitability in 2027.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.rutlandherald.com/news/business/alpha-cognition-inc-reports-first-quarter-2026-financial-results-and-provides-operational-update/article_e4156950-56e0-58b1-86a0-033a77763f3c.html